MBPhD projects available for 2023 intake

Project 1: Modelling Down Syndrome Acute Lymphoblastic Leukaemia in Induced Pluripotent Stem Cells

Primary supervisor: Tariq Enver, UCL Co-supervisor: Victor Tybulewicz, The Francis Crick Institute

Project 2: Development of allogeneic Natural Killer (NK) cells transduced with Chimeric Antigen Receptors (CARs) for paediatric and adult Acute Myeloid Leukaemia (AML) and high risk myelodysplasia (MDS)

Primary supervisor: Sara Ghorashian, UCL Co-supervisor: Shahram Kordasti, King’s College London

Project 3: Harnessing metabolomic methods to understand the molecular basis of cancer-associated cachexia

Primary supervisor: Mariam Jamal-Hanjani, UCL Co-supervisor: Charles Swanton, UCL/ The Francis Crick Institute

Project 1: Identifying ethnically relevant targets for improved treatment of ER+ breast cancer in British-Black women

Primary supervisor: Kairbaan Hodivala-Dilke, Queen Mary University of London Co-supervisors: Vicky Sanz Moreno, Queen Mary University of London, J Louise Jones, Queen Mary University of London, Anita Grigoriadis, King’s College London

Project 2: Deploying esters of the Krebs cycle metabolites to eliminate cancer stem cells in acute myeloid leukaemia

Primary supervisor: Kamil R Kranc, Queen Mary University of London Co-supervisor: Andrew Finch, Queen Mary University of London, Richard Dillon, King’s College London, Christopher Schofield, University of Oxford

Project 3: Understanding and exploiting the impact of NPM1 mutations in reshaping the nucleolus of Acute Myeloid Leukaemia

Primary supervisor: Faraz Mardakheh, Queen Mary University of London Co-supervisors: Paolo Gallipoli, Queen Mary University of London, Beth Payne, UCL

Project 4: Dissecting the phenotype and function of sub-types of breast cancer associated fibroblasts (CAFs)

Primary supervisor: John Marshall, Queen Mary University of London Co-supervisor: J Louise Jones, Queen Mary University of London

Project 5: Epigenetic targeting in pancreatic ductal adenocarcinoma to overcome resistance to immunotherapies

Primary supervisor: Oliver Pearce, Queen Mary University of London Co-supervisors: David Propper, Queen Mary University of London, Gerard Evan, The Francis Crick Institute